Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 2Fluorouracil 2rubitecan 1nimotuzumab 1halofantrine 1gallium 68 PSMA-11 1camrelizumab 1apatinib 1S 1 (combination) 1Radiotherapy 1Radiosurgery 1Radiation 1Photochemotherapy 1Nadroparin 1Heparin, Low-Molecular-Weight 1Gastrectomy 1Esophagectomy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1Capecitabine 1CP protocol 1Brachytherapy 1Atrasentan 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Adenocarcinoma × rubitecan × Clear all
NCT00113256 2024-08-02

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Astex Pharmaceuticals, Inc.

Phase 2/3 Terminated
39 enrolled
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡